A Phase 2, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Obeldesivir in Participants From Birth to < 5 Years of Age With Respiratory Syncytial Virus (RSV) Infection
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Obeldesivir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Jan 2025 New trial record